Morningside

Xealth Inc. operates a digital health prescribing platform that allows clinicians to integrate, prescribe, and monitor digital health tools directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, the platform facilitates patient engagement by enabling care teams to order appropriate digital health tools and programs, which can be sent to patients via email or patient portals. In addition to managing digital health prescriptions, the platform supports patient education and offers non-clinical services such as ride shares and food delivery. This comprehensive approach allows clinicians to monitor patient activity and engagement, ultimately enhancing the overall effectiveness of digital health initiatives within healthcare systems.

SimpliFed is a telehealth company founded in 2020 that offers virtual breastfeeding support to new and pregnant parents. The company focuses on providing accessible care during the peri and postnatal periods, addressing the challenges faced by parents, including sleep deprivation and concerns about infant nutrition. SimpliFed specializes in lactation and baby feeding support, as well as monitoring high-risk conditions such as hypertension and gestational diabetes. Through secure online and video-based connections, patients can engage with care navigators who guide them through their maternal care journey, helping them obtain quick answers to their questions about their infants' dietary needs.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

CairnSurgical is focused on creating innovative patient-specific tools designed to enhance the precision and accuracy of surgical interventions for cancer patients. The company utilizes patient imaging data combined with advanced 3D printing technologies to develop its image guidance devices. By providing healthcare professionals with tailored solutions, CairnSurgical aims to improve surgical outcomes and ensure that interventions are more effectively aligned with the unique anatomical features of each patient.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Curve Health, Inc. is an innovative online platform focused on enhancing senior care by integrating telemedicine, health information exchange, predictive analytics, and smart billing. Founded in 2020 and based in New York, the platform facilitates remote care for patients in skilled nursing facilities, at home, and in emergency situations, significantly reducing the need for patient transfers to emergency departments. By streamlining communication and operations between healthcare providers and post-acute facilities, Curve Health improves care quality and patient outcomes while optimizing resource allocation. The platform also accelerates reimbursement processes and automates documentation, making it a comprehensive solution for modern healthcare challenges in senior care.

Casana is a healthcare technology company based in Rochester, New York, that specializes in in-home cardiac health monitoring solutions. Its flagship product, the Heart Seat, is a cloud-connected toilet seat designed to allow patients to effortlessly monitor critical health metrics such as heart rate, blood pressure, blood oxygenation, and cardiac output from the comfort of their homes. The Heart Seat integrates three key sensors: a single-lead ECG for measuring the heart's electrical activity, PPG sensors that assess blood volume, and BCG sensors that track the mechanical activity of the heart. This innovative device aims to assist medical teams in managing chronic conditions by providing continuous, reliable health data outside traditional healthcare settings. Casana's technology is focused on fostering proactive health management and improving patient outcomes.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic company established in 2019 and headquartered in Suzhou, China, with a research and development office in Singapore. The company specializes in developing advanced diagnostic technologies aimed at infectious diseases, cancer, and chronic diseases. Its offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Through these technologies, Virtue Diagnostics aims to enhance disease detection and management, contributing to improved healthcare outcomes.

Ieso Digital Health Ltd. is a provider of online, evidence-based mental health therapy, focusing on cognitive behavioral therapy (CBT) delivered through a digital platform. The company offers one-to-one therapy sessions for various mental health issues, including anxiety, depression, and phobias, as well as support for chronic physical health problems and cognitive impairments. Ieso's innovative approach combines proprietary technology with natural language processing and artificial intelligence to enhance therapy delivery through real-time monitoring and assessment. This enables therapists to provide effective care in a virtual environment, allowing patients to access support at their convenience. Serving a diverse clientele that includes health providers, private individuals, and businesses, Ieso aims to transform mental healthcare by making it more accessible and scalable. Founded in 2000 and based in Swavesey, United Kingdom, Ieso was previously known as PsychologyOnline.co.uk Limited before rebranding in 2015.

Ieso Digital Health Ltd. is a provider of online, evidence-based mental health therapy, focusing on cognitive behavioral therapy (CBT) delivered through a digital platform. The company offers one-to-one therapy sessions for various mental health issues, including anxiety, depression, and phobias, as well as support for chronic physical health problems and cognitive impairments. Ieso's innovative approach combines proprietary technology with natural language processing and artificial intelligence to enhance therapy delivery through real-time monitoring and assessment. This enables therapists to provide effective care in a virtual environment, allowing patients to access support at their convenience. Serving a diverse clientele that includes health providers, private individuals, and businesses, Ieso aims to transform mental healthcare by making it more accessible and scalable. Founded in 2000 and based in Swavesey, United Kingdom, Ieso was previously known as PsychologyOnline.co.uk Limited before rebranding in 2015.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Huckleberry makes behavioral expertise accessible and affordable to all families by combining AI with human experts, starting with children's sleep.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

Linus Health, Inc. is a digital health company based in Waltham, Massachusetts, founded in 2019. It specializes in developing a brain health monitoring platform that utilizes digital screening technology to enhance the assessment and treatment of cognitive and mental health. The platform collects various digital measurements, including voice, speech, gait, cognition, and eye movement, aimed at early detection and diagnosis of brain health issues. Additionally, Linus Health provides clinical decision support and care planning tools, enabling healthcare providers to offer actionable recommendations based on the insights gathered. The company's mission focuses on transforming brain health, making it accessible to individuals worldwide.

Rockley Photonics Limited is a London-based company founded in 2013 that specializes in silicon photonics for various applications. The company develops a comprehensive range of photonic integrated circuits, sensors, and full-stack solutions aimed at high-volume markets. Rockley's technology is designed for next-generation sensing platforms, including mobile health monitoring and machine vision, as well as for high-speed data communications. By focusing on integrated optical modules, supporting electronics, software, and AI platforms, Rockley aims to establish a strong presence in dynamic and rapidly growing sectors. The company envisions photonics becoming as ubiquitous as microelectronics, leveraging its versatile platform to address diverse market needs.

Innodem Neurosciences, founded in 2016 and based in Outremont, Canada, specializes in developing artificial intelligence-driven mobile software technology focused on enhancing communication for paralyzed and intubated patients through eye movements. The company's flagship product, Pigio, utilizes eye-tracking technology to facilitate interaction between patients and caregivers. Additionally, Innodem's technology serves as a digital biomarker tool for diagnosing neurodegenerative diseases, enabling healthcare professionals to identify abnormalities, monitor disease progression, and evaluate treatment effectiveness. By providing patient self-testing capabilities, the company aims to improve the overall quality of life for patients and support clinicians in delivering more effective healthcare.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

CairnSurgical is focused on creating innovative patient-specific tools designed to enhance the precision and accuracy of surgical interventions for cancer patients. The company utilizes patient imaging data combined with advanced 3D printing technologies to develop its image guidance devices. By providing healthcare professionals with tailored solutions, CairnSurgical aims to improve surgical outcomes and ensure that interventions are more effectively aligned with the unique anatomical features of each patient.

Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, that focuses on developing digital diagnostics and therapeutics aimed at improving the early diagnosis and treatment of behavioral health conditions, such as autism. The company offers an online application that allows parents and caregivers to assess their children's cognitive development by answering questions about behavior and submitting videos of their child at play. This tool provides scores and personalized recommendations, helping users understand their child's risk for autism and other developmental delays. Additionally, Cognoa's responsible artificial intelligence technology identifies subtle signs of developmental issues, enabling healthcare providers to gain insights that support informed diagnoses. The company's mission is to enhance the lives and outcomes of children and families affected by behavioral conditions.

Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that focuses on developing applications for monitoring brain health. The company has created a multi-modal brain health analytics platform that utilizes advances in artificial intelligence, neuroscience, and speech analytics to detect changes in neurological health. By leveraging proprietary metrics, Aural Analytics transforms smartphones and tablets into effective brain health monitors, capturing subtle, clinically relevant aspects of a patient's condition through speech samples. This technology enhances traditional functional rating scales used in clinical trials by providing objective, continuous outcomes, thereby allowing for more reliable evaluations of drug efficacy and other interventions. Aural Analytics' platform aims to reveal incremental changes in neurological health, facilitating accurate assessments by medical professionals.

Rockley Photonics Limited is a London-based company founded in 2013 that specializes in silicon photonics for various applications. The company develops a comprehensive range of photonic integrated circuits, sensors, and full-stack solutions aimed at high-volume markets. Rockley's technology is designed for next-generation sensing platforms, including mobile health monitoring and machine vision, as well as for high-speed data communications. By focusing on integrated optical modules, supporting electronics, software, and AI platforms, Rockley aims to establish a strong presence in dynamic and rapidly growing sectors. The company envisions photonics becoming as ubiquitous as microelectronics, leveraging its versatile platform to address diverse market needs.

Biothea Pharma focuses on transforming the treatment landscape for severe allergic reactions and anaphylaxis. The company is dedicated to developing needle-free treatments that offer healthcare professionals convenient and cost-effective alternatives to traditional methods. By prioritizing innovation in this critical area of healthcare, Biothea Pharma aims to enhance patient safety and improve the overall management of allergic conditions.

Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, that focuses on developing digital diagnostics and therapeutics aimed at improving the early diagnosis and treatment of behavioral health conditions, such as autism. The company offers an online application that allows parents and caregivers to assess their children's cognitive development by answering questions about behavior and submitting videos of their child at play. This tool provides scores and personalized recommendations, helping users understand their child's risk for autism and other developmental delays. Additionally, Cognoa's responsible artificial intelligence technology identifies subtle signs of developmental issues, enabling healthcare providers to gain insights that support informed diagnoses. The company's mission is to enhance the lives and outcomes of children and families affected by behavioral conditions.

Keep is an innovative fitness platform that combines technology with a passion for sports, aiming to enhance the fitness experience for users. The company offers a comprehensive fitness solution that includes AI-assisted personalized curriculums, interactive live-streaming classes, and recorded fitness courses. These offerings are tailored to individual athletic levels, fitness goals, and daily workout habits. Additionally, Keep provides a range of smart fitness devices, gear, apparel, and nutritional products, creating an integrated ecosystem that bridges the physical and digital realms. By promoting a culture of fitness and encouraging community engagement, Keep seeks to inspire more individuals to embrace an active lifestyle.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

InSilixa, Inc. is a biotechnology company based in Sunnyvale, California, specializing in the development of high-performance CMOS biochips for molecular diagnostics. Founded in 2011, the company aims to democratize access to diagnostic testing by offering low-cost, high-performance solutions for DNA and protein-based testing. InSilixa focuses on creating point-of-care and near-patient platforms that enhance the efficiency and accessibility of genomic testing, particularly for the diagnosis of infectious diseases. By leveraging its proprietary semiconductor technology, InSilixa seeks to provide mass-deployable diagnostic tools that improve healthcare outcomes. The team comprises industry veterans with diverse expertise in semiconductor technology, biotechnology, medicine, and informatics.

DNAtrix, Inc. is a clinical-stage biotechnology company based in Texas that specializes in developing virus-driven immunotherapies for cancer treatment. The company’s leading product, DNX-2401, is an oncolytic immunotherapy designed to target and kill glioblastoma cells, a particularly aggressive form of brain cancer. This therapy has shown promising early results, with over 35 patients treated. DNAtrix is also developing additional armed DNX viruses, specifically DNX-2440 and DNX-2450, aimed at treating various solid tumors, as well as MYX-135, which targets hematological malignancies. With a focus on harnessing modified viruses to selectively destroy cancer cells while stimulating the immune system, DNAtrix seeks to expand its platform to address other cancers, including brain metastases, ovarian, and pancreatic cancers. The company was incorporated in 2005 and maintains its headquarters in Houston, Texas, with an additional office in San Diego, California.

Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, that focuses on developing digital diagnostics and therapeutics aimed at improving the early diagnosis and treatment of behavioral health conditions, such as autism. The company offers an online application that allows parents and caregivers to assess their children's cognitive development by answering questions about behavior and submitting videos of their child at play. This tool provides scores and personalized recommendations, helping users understand their child's risk for autism and other developmental delays. Additionally, Cognoa's responsible artificial intelligence technology identifies subtle signs of developmental issues, enabling healthcare providers to gain insights that support informed diagnoses. The company's mission is to enhance the lives and outcomes of children and families affected by behavioral conditions.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Kindstar Global (Beijing) Technology, Inc. is a Chinese enterprise that specializes in providing advanced clinical testing services, including esoteric diagnostic and laboratory testing, to hospitals across the country, particularly tertiary care facilities. Founded in 2003 and based in Wuhan, the company operates laboratory facilities in key cities such as Beijing, Shanghai, and Wuhan. Kindstar Global is committed to enhancing personalized medicine and specialized clinical services by developing innovative testing technologies and methods. In addition to diagnostic services, the company offers medical research, clinical trial services, and translational medicine studies, catering to the needs of physicians, medical institutions, and pharmaceutical companies. The organization adheres to international standards and guidelines to prioritize patient interests and healthcare provider requirements.

ProterixBio, Inc. develops disease management platforms aimed at improving outcomes for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company focuses on creating proprietary blood-based biomarker tests that provide real-time biological assessments of a patient's disease state. Its ViBE platform, along with Acoustic Membrane MicroParticle (AMMP) assays, utilizes advanced technology to enhance the sensitivity and specificity of traditional diagnostic methods by analyzing proteins in blood, sputum, and other samples. By offering tools that enable healthcare providers to better manage patients, ProterixBio aims to reduce unnecessary hospitalizations and associated healthcare costs. Founded in 2002 and headquartered in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in 2016.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

HD Biosciences Inc. is a Shanghai-based biotechnology company that specializes in contract research for drug discovery. The company has developed a comprehensive range of technology platforms and expertise in areas such as assay development, high throughput drug screening, structure-activity relationship (SAR) studies, and hit-to-lead biology solutions. Additionally, it focuses on natural product-based lead discovery. HD Biosciences has established long-term research agreements with notable clients, including Pfizer and Organon, positioning itself as a leader in biology-based drug discovery in China. Its services encompass a variety of stages in the drug discovery process, from assay development and validation to hit identification and in vivo pharmacology, catering to the needs of pharmaceutical and biotech companies globally.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Serica Technologies, Inc. is a medical device company based in Medford, Massachusetts, specializing in biodegradable, silk-based biomaterial platforms designed for tissue repair. The company develops a range of products, including SeriGel, a bioresorbable silk hydrogel used in plastic and reconstructive surgery, and the SeriFascia surgical scaffold implant, which aids in restoring functional collagen tissue lost due to surgery or aging. Additionally, Serica offers the SeriACL graft for anterior cruciate ligament repair, the SeriCuff scaffold for rotator cuff tendon repair, and the SeriScaffold surgical mesh for the repair of damaged connective tissues. These innovative products serve various applications in orthopedics, sports medicine, and aesthetic and reconstructive plastic surgery. Originally founded as Tissue Regeneration, Inc. in 1998, the company rebranded in 2006 and has since operated as a subsidiary of Allergan Inc.